MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer.

In the subgroup with tumor length ≥ 5 cm, nICRT also showed a numerically higher pCR rate, although the difference did not reach statistical significance (OR, 2.99; 95% CI, 0.79–11.27; P = 0.107). 3.6 ROC analysis The MRI-based risk stratification system combining mrEMVI, mrMRF, and tumor length ≥ 5 cm yielded an AUC of 0.835 (95% CI, 0.767–0.902), indicating good discrimination between patients with and without pCR ( Figure 4 ).

also in 111,027 other papers